Trial · NCT03880877
Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer
NCT03880877, Phase 2, Unknown, Kaohsiung Medical University Chung-Ho Memorial Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer. Trials, record NCT03880877. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03880877
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer
- NCT number
- NCT03880877
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 153 participants, estimated
- Lead sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Regorafenib, UGT1A1 genotyping (TA6/TA6), UGT1A1 genotyping (TA6/TA7), UGT1A1 genotyping (TA7/TA7), Leucovorin and 5-FU
- First posted
- 2019-03-19
- Last updated
- 2019-03-21
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival | From date of initiation of treatment until the date of first documented progression, assessed up to 23 months | Time from treatment to disease progresses and lives |
| Secondary | Overall survival | From date of initiation of treatment until the date of death from any cause, assessed up to 23 months | Time from treatment to death of patients |
| Secondary | Best objective response | From date of initiation of treatment until the date of disease progression, assessed up to 23 months | best response recorded during treatment |
| Secondary | Disease control rate | From date of initiation of treatment until the date of disease progression, assessed up to 23 months | Rate of best objective response, including complete response, partial response and stable disease |
| Secondary | Time to progression | From date of initiation of treatment until the date of disease progression, assessed up to 23 months | Time from treatment to disease progresses |
| Secondary | Duration of treatment | From date of initiation of treatment until the date of disease progression, assessed up to 23 months | Time from initiation to termination of treatment |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03880877
GET https://conductscience.org/api/trials/v1/NCT03880877/registered